Professor Nick Turner leads his group in the Manchester Institute of Biotechnology (MIB) and is the Managing Director of CoEBio3. CoEBio3 is the UK centre for Industrial Biotechnology research and has its main facility at The University of Manchester. It has an applied “genes to kilos” philosophy working closely with 12 Industrial affiliate partners.
The Turner research groups have over 30 years’ experience in biocatalysis and Nick has published over 400 papers in this field primarily focused on the use of enzymes as biocatalysts for organic synthesis, with experience of a wide range of different enzymes, mainly oxidases including P450s. The MIB laboratory is fully equipped to be able to carry out organic synthesis, analytical chemistry, microbiology, protein biochemistry and molecular biology. Specific equipment available includes Agilent LC-MS systems, capillary electrophoresis, chiral HPLC, chiral GC-MS, Akta protein purification, Tecan robot, plate-readers, CEM microwave equipment for synthesis and peptide synthesis and Accelrys DS-Modeling software for protein modeling.
Within the ROBOX project Manchester will develop the use of Cytochrome P450 enzymes to produce drug metabolites which will then be used to make new drugs safer and lead to the development of better drugs
Project Exploitation, Intellectual Property Management, Dissemination and Public Engagement (workpage 6) will be led by Dr John Whittall. John is the Research Exploitation Manager at CoEBio3 and has more than 40 years’ experience working in the research environment at the academic-industry interface.
Image from our ROBOX publication http://onlinelibrary.wiley.com/wol1/doi/10.1002/cctc.201700620/full
“The research for this work has received funding from the European Union (EU) project ROBOX (grant agreement n° 635734) under EU’s Horizon 2020 Programme Research and Innovation actions H2020-LEIT BIO-2014-1”